statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Gyre Therapeutics Seeks Compliance Amid Board Reshuffle

Gyre Therapeutics (GYRE) has shared an announcement. Gyre Therapeutics, Inc. has reported a vacancy on its Audit Committee following the resignatio...

Gyre Therapeutics (GYRE, $15.85) price exceeded its 50-day Moving Average on April 01, 2024

This price move could indicate a change in the trend, and may be a sell signal for investors...

Gyre Therapeutics Inc (GYRE) Announces Full Year 2023 Financial Outcomes and Business Progress

Transformational Year with Strategic Shifts and Clinical AdvancesRelated Stocks: GYRE...

Gyre Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update

Data readout from Phase 3 clinical trial in the People's Republic of China ( PRC ) evaluating F351 for the treatment of CHB-associated liver fibrosis expected by early 2025 U.S. Phase 2a clinical...

Gyre Therapeutics GAAP EPS of -$1.41, revenue of $113.5M

Gyre Therapeutics GAAP EPS of -$1.41, revenue of $113.5M...

Gyre Therapeutics Expands Board of Directors with Appointment of Rodney L. Nussbaum

SAN DIEGO, March 21, 2024 (GLOBE NEWSWIRE) -- Gyre Therapeutics ( Gyre ) (Nasdaq: GYRE), a clinical-stage biotechnology company developing anti-fibrotic therapeutics for a variety of chronic organ...

Gyre Therapeutics (GYRE, $16.76) price exceeded its 50-day Moving Average on March 15, 2024

Gyre Therapeutics (GYRE, $17.24) price exceeded its 50-day Moving Average on March 08, 2024

Gyre Therapeutics (GYRE, $18.14) RSI Indicator left the overbought zone on February 29, 2024

This is a signal that GYRE's price could be shifting from an uptrend to a downtrend. Traders may consider selling the stock or exploring put options...

Gyre Therapeutics (GYRE, $18.14) price exceeded its 50-day Moving Average on February 29, 2024

Gyre Therapeutics, Inc. operates as a biopharmaceutical company. It is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis). The firm operates through the BC and Gyre segments. The company was founded on March 7, 1997 and is headquartered in San Diego, CA.

Volume	32,303.00
52-Wk High	$30.40
52-Wk Low	$4.80

GYRE Gyre Therapeutics Inc

About

Feed

News

Sentiment

Fundamentals